Clinical study of docetaxel combined with tegafur, gimeracil and oteracil potassium capsules in treatment of advanced esophagogastric junction adenocarcinoma
10.3781/j.issn.1000-7431.2011.12.012
- Author:
Guo-Zhi HU
1
Author Information
1. Department of Medical Oncology
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma of esophagogastric junction;
Antineoplastic combined chemotherapy protocols;
Docetaxel;
Tegafur, gimeracil and oteracil potassium capsule
- From:
Tumor
2011;31(12):1111-1115
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and toxicity of docetaxel combined with tegafur,gimeracil and oteracil potassium (S-1) capsules in the treatment of patients with advancedadenocarcinoma of esophagogastric junction (AEG). Methods: Fifty-eight patients with advanced AEGwere recruited in this study between January 2009 and January 2011. All patients were treated withchemotherapy of docetaxel (35 mg·m-2·d-1 on d 1 and d 8; intravenous injection) combined with S-1capsule (70 mg/m2 daily for 14 days). The chemotherapy cycle was repeated every 21 days. The short-termresponse and the toxicity were evaluated every two cycles and one cycle, respectively. The follow-upexaminations were performed in all patients, and the survival was calculated. Results: Of the 58 patients,there were 5 patients (8.6%) with complete response, 21 patients (36.2%) with partial response, 18patients (31.0%) with stable disease, and 14 patients (24.1%) with progressive disease. The total responserate was 44.8% (26/58). The median time to progression was 8.0 months, and the median survival timewas 10.5 months. The major toxicities included leucopenia, stomatitis, hand-foot syndrome and adversereactions of gastrointestinal tract. The rate of grade ¢ó-¢ô leucopenia was 25.9% (15/58). Conclusion: Docetaxel combined with S-1 capsule is effective and tolerable in the treatment of patients with advanced AEG. Copyright© 2011 by TUMOR.
